Technical rebound gains traction: Investors on social media highlight Pfizer's recent hammer candle formation after retesting prior resistance now acting as support, signaling downside rejection and potential uptrend continuation. Traders express patience rewarded as shares grind higher from $21 to near $27, with a break above $28 eyed for further gains.
Pipeline developments draw focus: Chatter centers on promising trial data for Braftovi in BRAF-mutant colorectal cancer, extending progression-free survival. Optimism surrounds the STAT6 program as a key pipeline needle-mover potentially adding billions in peak sales. Institutional moves, like Norges Bank's substantial new stake, bolster confidence.
Yield and options activity noted: The stock's attractive 6.45% forward yield shines despite COVID sales drop, supporting 7.7% year-to-date returns. Short-term call options targeting $28 strikes reflect trader interest in near-term upside. Overall sentiment tilts positive amid post-pandemic navigation.
Note: This discussion summary was generated from an AI condensation of post data.
Pfizer Revenue
Pfizer had revenues of $17.6B in Q4 2025. This is a decrease of -1.17% from the same period in the prior year.
You can track PFE financials on Quiver Quantitative's PFE stock page.
Pfizer Congressional Stock Trading
Members of Congress have traded $PFE stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- REPRESENTATIVE J. FRENCH HILL sold up to $250,000 on 12/31.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 11/18 and 1 sale worth up to $15,000 on 12/19.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Pfizer Hedge Fund Activity
We have seen 1,252 institutional investors add shares of Pfizer stock to their portfolio, and 1,588 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 101,068,901 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $2,516,615,634
- NORGES BANK removed 20,119,761 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $500,982,048
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 17,862,459 shares (-96.2%) from their portfolio in Q4 2025, for an estimated $444,775,229
- PACER ADVISORS, INC. removed 17,574,851 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $437,613,789
- MORGAN STANLEY added 14,342,946 shares (+19.2%) to their portfolio in Q4 2025, for an estimated $357,139,355
- BANK OF NEW YORK MELLON CORP added 13,581,757 shares (+38.9%) to their portfolio in Q4 2025, for an estimated $338,185,749
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 8,837,922 shares (-70.2%) from their portfolio in Q4 2025, for an estimated $220,064,257
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Pfizer Government Contracts
We have seen $492,563 of award payments to $PFE over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PFIZER VACCINES STORAGE AND ROTATION CONTRACT: $410,203
- 4569494415!PROCARDIA XL 30 MG TABLET 100S: $24,723
- 4568572944!NALOXONE 4 MG/10 ML VIAL 10ML: $11,280
- 4568676827!HEXTEND 6%-LACT ELEC BAG 500ML: $11,164
- 4568256080!NALOXONE 4 MG/10 ML VIAL 10ML: $8,460
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Pfizer Analyst Ratings
Wall Street analysts have issued reports on $PFE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/24/2025
To track analyst ratings and price targets for Pfizer, check out Quiver Quantitative's $PFE forecast page.
Pfizer Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 9 analysts offer price targets for $PFE in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Trung Huynh from RBC Capital set a target price of $25.0 on 02/25/2026
- Emily Field from Barclays set a target price of $25.0 on 02/20/2026
- Carter Gould from Cantor Fitzgerald set a target price of $27.0 on 02/04/2026
- Michael Yee from UBS set a target price of $25.0 on 01/07/2026
- Terence Flynn from Morgan Stanley set a target price of $27.0 on 12/17/2025
- Jason Gerberry from B of A Securities set a target price of $28.0 on 12/15/2025
- Geoff Meacham from Citigroup set a target price of $26.0 on 12/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
